Table 4.
Association between PFS and clinical factors or cytokines in plasma by univariate analysis.
| Factor | Hazard Ratio (95% CI) | P |
|---|---|---|
| Age (years) | 1.021 (0.960–1.085) | 0.513 |
| Gender (Male vs. Female) | 2.511 (0.908–6.948) | 0.076 |
| Smoking (Never vs. Ever) | 1.138 (0.428–3.022) | 0.796 |
| Pathology (ADC vs. SCC) | 0.596 (0.245–1.453) | 0.255 |
| Stage* (IIB vs. IIIA vs. IIIB) | 1.679 (0.750–3.755) | 0.207 |
| EGFR mutation (wildtype vs. mutant) | 2.212 (0.622–7.861) | 0.220 |
| Induction chemotherapy (No vs. Yes) | 0.606 (0.238–1.542) | 0.293 |
| CCL5 | 0.987 (0.961–1.015) | 0.357 |
| CXCL3 | 0.999 (0.997–1.000) | 0.121 |
| Eotaxin | 0.999 (0.991–1.007) | 0.812 |
| EPO | 1.005 (0.984–1.027) | 0.651 |
| FLT3L | 0.997 (0.993–1.002) | 0.218 |
| G-CSF | 1.009 (0.993–1.026) | 0.284 |
| GM-CSF | 0.465 (0.002–109.226) | 0.783 |
| ICAM-1 | 1.001 (1.000–1.001) | 0.070 |
| IFN-γ | 1.011 (0.996–1.027) | 0.143 |
| IL-1α | 1.001 (0.766–1.310) | 0.992 |
| IL-1β | 4.388 (0.165–117.024) | 0.377 |
| IL-10 | 0.225 (0.036–1.395) | 0.109 |
| IL-12p70 | 0.952 (0.879–1.032) | 0.235 |
| IL-13 | 0.979 (0.855–1.121) | 0.759 |
| IL-2 | 1.149 (0.680–1.940) | 0.605 |
| IL-6 | 0.985 (0.845–1.147) | 0.845 |
| IL-8 | 0.788 (0.630–0.985) | 0.036 |
| IP-10 | 0.998 (0.995–1.001) | 0.152 |
| M-CSF | 1 (0.989–1.010) | 0.953 |
| sPD-L1 | 1.001 (1.000–1.002) | 0.117 |
| TNF-α | 0.974 (0.710–1.336) | 0.869 |
| TPO | 0.999 (0.996–1.002) | 0.550 |
| TRAIL | 0.984 (0.963–1.006) | 0.155 |
| VEGF | 0.978 (0.947–1.009) | 0.155 |
| WNT3A | 1.333 (0.589–3.020) | 0.491 |
Cytokines with P<0.1 are shown in bold. *According to American Joint Commission on Cancer (AJCC) staging system 7th edition.